1,054 results
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
is settling these cases, not because Sanofi believes the claims have any merit, but rather to avoid expenses and ongoing distraction of the litigation … million mainly related to redundancy plans announced during Q1 2024 and separation costs of the CHC business.
Other gains and losses, and litigation
F-3ASR
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
is sued by a third party and ultimately prevails in the litigation on all counts, but is nevertheless required to bear attorneys’ fees and costs
F-3ASR
EX-25.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
)
Y924
2.m.
TEXT
Services rendered by affiliates
2.n.
TEXT
Litigation Expenses
2.o.
TEXT 4468
2.p.
3. Discontinued operations and applicable income
S-8
SNY
Sanofi
4 Apr 24
Registration of securities for employees
8:45am
is sued by a third party and ultimately prevails in the litigation on all counts but is nevertheless required to bear attorneys’ fees and costs
6-K
EX-99.1
SNY
Sanofi
20 Mar 24
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
2:07pm
in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements … and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates
6-K
EX-99.4
dqr6ime q4crh47
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.5
wfh4k46mnzas
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.2
ca23lvfd3f n8
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.1
m78q3fhj
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.1
afp0816j6 1s25apfp8u
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
6-K
EX-99.1
bfugngk2
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
6-K
EX-99.1
kij4urca7tmu91u
23 Jan 24
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
7:23am
6-K
EX-99.1
po72mdwl
27 Dec 23
Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
11:18am
6-K
EX-99.4
zb9nl1c5zdd03vg63e
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.5
nbwxf989c2ud n8
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.2
cnn9r0hz mdiz
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.3
tosat9
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.1
6jtwtj 10fqi
20 Dec 23
Current report (foreign)
10:39am
F-6EF
EX-99
1aw4 itt9uufmkznkm
18 Dec 23
Automatic registration for ADRs (foreign)
5:23pm
6-K
EX-99.1
ve14ot9hq9 j1p
1 Dec 23
Current report (foreign)
12:19pm